Skip to main content

Erasca, Inc.

corporate_fare Company Profile

Erasca, Inc.

ERAS·NASDAQ·Life Sciences·CIK 0001761918

Erasca is a clinical-stage precision oncology company focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Molecular alterations in RAS and the MAPK pathway account for more than five million new patients diagnosed with cancer globally each year. The company was co-founded by pioneers in precision oncology and RAS targeting to create novel therapies and combination regimens designed to shut down the RAS/MAPK pathway. Erasca's RAS/MAPK pathway pipeline includes modality-agnostic programs aligned with three therapeutic strategies: targeting key upstream and downstream signaling nodes in the RAS/MAPK pathway; targeting RAS directly; and targeting escape routes that emerge in response to treatment. This approach allows for a systematic, data-driven, portfolio-wide clinical development effort to identify therapeutic approaches aimed at prolonging survival in patient populations with high unmet medical needs. The modality-agnostic approach enables selective and potent targeting of critical signaling nodes with the most appropriate modality, including small and large molecule therapeutics. The pipeline includes two clinical-stage programs: ERAS-0015, a pan-RAS molecular glue; and ERAS-4001, a pan-KRAS inhibitor. It also includes ERAS-12, a discovery-stage program (an EGFR D2/D3 biparatopic antibody), for which a lead candidate has been identified.

Erasca, Inc. (NASDAQ:ERAS) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 40 items for ERAS at importance 7 or higher on its 1–10 market-impact scale.

Recent high-impact activity:

  • Erasca Shares Plunge 48% on Lead Asset IP Challenge; Law Firm Investigates Misleading Claims
  • Erasca Reports Q1 Loss of $183.4M Driven by $150M License Expansion, Discloses Patient Death in Trial, and Patent Dispute
  • Erasca's Q1 Net Loss Widens to $183.4M on Increased R&D Spending
  • Erasca Announces Merck Collaboration for ERAS-0015, Reports Strong Cash Position and Q1 Results
  • Erasca Partners with Merck for KEYTRUDA Combination Trial of Pan-RAS Molecular Glue ERAS-0015

Financial Snapshot

Fiscal year ended December 31, 2025
Net Income
-$124.55M
Diluted EPS
-$0.44
Op. Cash Flow
-$95.45M
Free Cash Flow
-$95.58M
Operating Income
-$140.91M
Cash & Equivalents
$73.81M
Debt / Equity
0.00×
Shares Outstanding
284.16M sh
Source: 10-K · filed 2026-03-12 · accession 0001193125-26-104150
$13.74 +0.96% today
52-week range · as of 2026-11-20 $2.75 – $24.28
Market cap
$4.78B
Volume
11.1M (2.0× avg)
3-mo avg 5.7M
Live data · 2026-11-22 03:53 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed ERAS - Filings & News (Page 2)

ERAS
May 28, 2026, 9:00 AM EDT
Source: PR Newswire
Importance Score:
9
Price at Filing: $12.46
Real-time Price: $13.74 info
Change: +$1.28 (+10%) info
Market Cap: $4.777B info
ERAS
May 11, 2026, 4:13 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $10.20
Real-time Price: $13.74 info
Change: +$3.54 (+35%) info
Market Cap: $4.777B info
ERAS
May 11, 2026, 4:09 PM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $10.50
Real-time Price: $13.74 info
Change: +$3.24 (+31%) info
Market Cap: $4.777B info
ERAS
May 11, 2026, 4:05 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $10.50
Real-time Price: $13.74 info
Change: +$3.24 (+31%) info
Market Cap: $4.777B info
ERAS
May 11, 2026, 7:00 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $10.18
Real-time Price: $13.74 info
Change: +$3.56 (+35%) info
Market Cap: $4.777B info
ERAS
Apr 28, 2026, 3:58 PM EDT
Source: Dow Jones Newswires
Importance Score:
9
Price at Filing: $10.01
Real-time Price: $13.74 info
Change: +$3.73 (+37%) info
Market Cap: $4.777B info
ERAS
Apr 27, 2026, 4:17 PM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $12.30
Real-time Price: $13.74 info
Change: +$1.44 (+12%) info
Market Cap: $4.777B info
ERAS
Apr 27, 2026, 8:31 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $23.46
Real-time Price: $13.74 info
Change: -$9.72 (-41%) info
Market Cap: $4.777B info
ERAS
Apr 21, 2026, 9:10 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $22.21
Real-time Price: $13.74 info
Change: -$8.47 (-38%) info
Market Cap: $4.777B info
ERAS
Mar 12, 2026, 4:11 PM EDT
Filing Type: 10-K
Importance Score:
8
Price at Filing: $14.71
Real-time Price: $13.74 info
Change: -$0.970 (-7%) info
Market Cap: $4.777B info
ERAS
Mar 12, 2026, 4:05 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $14.65
Real-time Price: $13.74 info
Change: -$0.9111 (-6%) info
Market Cap: $4.777B info
ERAS
Mar 12, 2026, 4:01 PM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $14.74
Real-time Price: $13.74 info
Change: -$1.00 (-7%) info
Market Cap: $4.777B info
ERAS
Mar 10, 2026, 8:00 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $15.90
Real-time Price: $13.74 info
Change: -$2.16 (-14%) info
Market Cap: $4.777B info
ERAS
Mar 05, 2026, 7:01 AM EST
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $15.15
Real-time Price: $13.74 info
Change: -$1.41 (-9%) info
Market Cap: $4.777B info
ERAS
Jan 29, 2026, 4:30 PM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $10.40
Real-time Price: $13.74 info
Change: +$3.34 (+32%) info
Market Cap: $4.777B info
ERAS
Jan 22, 2026, 5:12 PM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $10.30
Real-time Price: $13.74 info
Change: +$3.44 (+33%) info
Market Cap: $4.777B info
ERAS
Jan 22, 2026, 5:10 PM EST
Filing Type: 424B5
Importance Score:
7
Price at Filing: $10.30
Real-time Price: $13.74 info
Change: +$3.44 (+33%) info
Market Cap: $4.777B info
ERAS
Jan 20, 2026, 4:05 PM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $9.00
Real-time Price: $13.74 info
Change: +$4.74 (+53%) info
Market Cap: $4.777B info
ERAS
Jan 20, 2026, 4:03 PM EST
Filing Type: 424B5
Importance Score:
8
Price at Filing: $8.90
Real-time Price: $13.74 info
Change: +$4.84 (+54%) info
Market Cap: $4.777B info
ERAS
Jan 12, 2026, 8:02 AM EST
Filing Type: 8-K
Importance Score:
9
Price at Filing: $6.76
Real-time Price: $13.74 info
Change: +$6.98 (+103%) info
Market Cap: $4.777B info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets